Table 1.
Reference, Study type | Patients | Syndrome | Mean follow-up | DBS target | Uni/bilateral stimulation | Off assessment time∧ | Outcome* | Exclusion & other |
---|---|---|---|---|---|---|---|---|
Rehncrona et al. (17), prospective |
N = 25 Exclusion = 14 |
ET and PD | ET: 6.5 yrs PD: 6.6 yrs |
VIM | ET: 17/2 PD: 19/0 |
2-year: 4-hours 6–7 years: 1-hour |
ET 2-year delta: 49% 6–7-year delta: 47% Loss of benefit: 4% PD 2-year delta: 77% 6–7-year delta: 54.5% Loss of benefit: 29% |
ET N = 6 (3 dead, 1 refused, 1 lost, 1 battery life end) PD N = 8 (4 dead, 2 refused, 2 lost) |
Sydow et al. (18), prospective |
N = 19 Exclusion = 7 |
ET | 6.54 yrs | VIM | Baseline: 15/4 6-years: 12/7 |
UN | 1-year delta: 45.6% 6-year delta: 46.3% Gain of benefit: 1% |
N = 7 (1 stopped due to SE, 3 dead, 1 refused, 1 lost, 1 battery life end) |
Blomstedt et al. (21), prospective |
N = 19 Exclusion = 8 |
ET | 7.17 yrs | VIM | UN | UN | Initial (mean 13 months): delta: 52% Final (86 months) delta: 30% Loss of benefit: 42% |
N = 8 (3 diagnosis revised, 4 died, 1 lost) |
Favilla et al. (12), retrospective |
N = 28 Controls = 21 Excluded = 41 |
ET | >36 months | VIM | 19/9 | 30 mins | Unilateral 6 months delta: 27% 36 months delta: 26% Loss of benefit: 4% Bilateral 6 months delta: 63% 36 months delta: 37% Loss of benefit: 41% |
N = 41 (10 prior DBS outside facility, 4 stimulator revision, 13 lost, 11 follow-up <24months) |
Fytagoridis et al. (33), prospective | N = 18 | ET | 4.04 yrs | cZI | 16/2 | DBS deactivated overnight | 1-year delta: 54.5% 3-5-year delta: 51.4% Loss of benefit: 6% |
- |
Cury et al. (29), retrospective | N = 98 | ET, PD & DT | ET: 8.1 yrs PD: 10.2 yrs DT: 10.8 yrs |
VIM | ET = 35/3 PD = 24/30 DT = 2/4 |
60 mins | PD Bilateral 1-year delta:73% 11–15 year delta: 69% 16–21 years delta: 60% Loss of benefit: 18% Unilateral 1-year delta: 67% 11–16 years delta: 58% 16–21 years delta: 63% Loss of benefit: 6% ET year delta: 66% >10 years delta: 48% Loss of benefit: 27% DT Delta: UN |
DT 4/6 received GPi DBS after VIM DBS, 3 due to lack of efficacy and intolerable side effects |
Tsubio et al. (32), retrospective | N = 124 Exclusion = 40 | ET & DT | ET: 3.5 yrs DT: 3.4 yrs |
VIM | ET: 72/25 DT: 17/9 |
At least 30 mins | ET 6-month delta: 50% 1–year delta: 42% 2–3 year delta: 37% 4–5 year delta: 38% 6year delta: 34% Loss of benefit: 32% DT 6-month delta: 42% 1–year delta: 45% 2–3 year delta: 41% 4–5 year delta: 8% 6–year delta: 42% No loss or gain of benefit |
N = 40 (24 alternative diagnosis and 16 lack of assessments) |
cZI, caudal zona incerta; DBS, deep brain stimulation; DT, dystonic tremor; ET, essential tremor; GPi, globus pallidus internus; N, number; PD, Parkinson Disease; PSA, posterior subthalamic area; SE, side effect; UN, unknown; VIM, ventralis intermedis nucleus of thalamus.
Time after DBS was switched off.
Statistical significance of delta at each time point or change in delta overtime (loss or gain of benefit) were not able to be verified.